Verrica Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCA research report →
Range $9 – $9
Price Chart
About the company
Verrica Pharmaceuticals Inc. , a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
- CEO
- Jayson Rieger
- IPO
- 2018
- Employees
- 76
- HQ
- West Chester, PA, US
Get TickerSpark's AI analysis on VRCA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $47.07M
- P/E
- -1.26
- Fwd P/E
- 1.92
- PEG
- 0.03
- P/S
- 2.17
- P/B
- -10.29
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 81.15%
- Op Margin
- -183.15%
- Net Margin
- -189.23%
- ROE
- -442.78%
- ROIC
- -222.71%
Latest fiscal year · YoY change
- Revenue
- $35.58M+370.2%
- Gross Profit
- $32.14M+565.9%
- Op Income
- $-11,939,000
- Net Income
- $-17,886,000+76.6%
- EPS
- $-1.68+88.6%
- OCF Growth
- +71.1%
- FCF Growth
- +71.1%
- 52W High
- $9.82
- 52W Low
- $2.73
- 50D MA
- $3.85
- 200D MA
- $5.30
- Beta
- 1.67
- RSI (14)
- 34
- Avg Volume
- 68.78K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Verrica posted record quarterly YCANTH revenue, improved gross margin, and advanced its common warts Phase III program while adding a new Gorlin syndrome development path for VP-315.· November 12, 2026
- Total revenue was $6.9 million, with record U.S. YCANTH net product revenue of $5.7 million, up 11.9% sequentially and 57.9% year over year.
- Gross product margin improved to 89.8% from 79.1% a year ago, helped by stronger product economics and improved commercial execution.
- Common warts development advanced: COVE-2 enrollment was completed and COVE-3 enrollment was above 50%, with readouts expected in Q1 2027 and mid-2027.
- Verrica unlocked the remaining $15 million under its credit facility after meeting milestones, extending liquidity to support the Phase III common warts program.
- Management said VP-315 is now being explored in Gorlin syndrome as a proof-of-concept opportunity, building on sporadic BCC data and FDA feedback.
Third-quarter 2026 total revenue was $6.9 million versus $14.3 million in the third quarter of 2025; the prior-year quarter included a one-time $10 million milestone payment from Torii. U.S. net YCANTH product revenue was $5.7 million, up from $3.6 million a year ago. Gross product margins were 89.8% versus 79.1% in the prior-year quarter. GAAP net loss was $12.4 million, or $0.58 per share, compared with a GAAP net loss of $0.3 million, or $0.03 per share, a year ago; non-GAAP net loss was $10.5 million, or $0.49 per share, versus non-GAAP income of $1.1 million, or $0.12 per share. As of September 30, 2026, cash was $14.4 million, including the $12.5 million borrowing from the credit facility. Management said that assuming use of the remaining $15 million available under the facility, cash runway could extend beyond the common warts data readouts and into the fourth quarter of 2027.
Jayson Rieger emphasized that the quarter showed record YCANTH revenue for the second straight quarter and meaningful progress in the pipeline. He highlighted the common warts Phase III program, the newly available $15 million in borrowing capacity, and the potential for VP-315 to be developed in Gorlin syndrome. His tone was upbeat and focused on execution, saying the company is well positioned to keep investing across its strategic initiatives.
John Kirby said the revenue decline versus last year was mainly due to the prior-year Torii milestone, while U.S. YCANTH product revenue increased on higher deliveries and improved yield. He noted research and development expense rose to $7.6 million, primarily because of $3.7 million tied to the common warts Phase III program and $1.3 million more in chemistry, manufacturing and controls spending; he also said the common warts trial expense has been non-cash so far because Torii funds the first $40 million of the program. Selling, general and administrative expense was $10.4 million, and he said cash of $14.4 million plus the remaining facility availability could fund operations through the key common warts readouts and into Q4 2027.
Analysts pressed on YCANTH growth drivers, access, seasonality, and whether improved yield was temporary; management said growth is coming from better targeting and segmentation, moving prescribers from “dabblers” to loyalists, and improved routing of medical-benefit prescriptions into in-network pharmacies. On common warts, management clarified the interim analysis was a blinded “promising zone” review rather than a formal futility analysis, and said no additional patients were recommended for COVE-2. Questions on Gorlin centered on whether it would be a separate proof-of-concept path and how it fits with the existing sporadic BCC program; management said the Gorlin work is being finalized now, could inform the broader Phase III strategy, and is intended to deepen understanding of VP-315 rather than replace the existing plan.
The core YCANTH business is still growing, with record quarterly revenue, year-over-year unit growth, and management saying yield per prescription is improving as access and channel optimization mature. The common warts opportunity remains large in management’s view, and the company now has funding visibility through the pivotal program readouts. VP-315 also gained a new potential development path in Gorlin syndrome, which management believes could address a severe unmet need and generate differentiated clinical data.
Revenue still depends on a relatively concentrated product base, and the quarter benefited from prior-year milestone comparisons, which makes the headline year-over-year revenue decline look large despite product growth. Management acknowledged Q4 seasonality and continued challenges from the entrenched watch-and-wait mindset in molluscum, plus the practical complexity of converting medical-benefit claims into the right channel. On the pipeline side, both common warts and Gorlin remain in development, so the commercial upside is still contingent on future clinical readouts, regulatory steps, and successful execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 51.0%
- Shares Outstanding
- 17.18M
- Float Shares
- 8.76M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Caligan Partners LP | 923.91K | 0 |
| Cannell Capital LLC | 693.55K | ▼ 90.37K |
| Affinity Asset Advisors, LLC | 688.65K | ▼ 18.68K |
| Vanguard Capital Management LLC | 351.91K | ▲ 72.60K |
| Boothbay Fund Management, LLC | 280.73K | 0 |
| Mariner, LLC | 214.03K | ▲ 6.80K |
| Armistice Capital, LLC | 206.47K | ▼ 219.83K |
| Vanguard Group Inc | 138.19K | ▼ 87.02K |
| Geode Capital Management, LLC | 128.30K | ▼ 9.86K |
| Blackrock, Inc. | 72.10K | ▼ 2.25K |
| Vanguard Fiduciary Trust Co | 53.51K | ▼ 16.67K |
| Two Sigma Advisers, LP | 44.43K | ▲ 44.43K |
Held by 22 ETFs
Biggest fund positions in VRCA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Zawitz David | buy | 6,000 |
| Aug 17, 26 | Rieger Jayson | buy | 5,000 |
| Aug 14, 26 | Rieger Jayson | buy | 20,000 |
| Aug 18, 26 | Rosenberg Noah L. | buy | 2,030 |
| Aug 17, 26 | Rosenberg Noah L. | buy | 4,200 |
| Aug 18, 26 | Kirby John J. | buy | 5,000 |
| Jun 5, 26 | Eichenfield Lawrence | other | 16,000 |
| Jun 5, 26 | Nguyen Diem | other | 16,000 |
| Jun 5, 26 | PRYGOCKI MARK A SR | other | 16,000 |
| Jun 5, 26 | Rosenberg Noah L. | other | 233,840 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRCA coverage
Recent articles, reports, and earnings notes.
No research on VRCA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRCA report →Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Verrica Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 13
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 12
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 10
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
globenewswire.com · Nov 5
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
globenewswire.com · Oct 22
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to Brokerages
defenseworld.net · Oct 12
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.